Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis
European Journal of Neurology, 08/16/2011
Clinical Article
Cocito D et al. – One–fourth of patients, refractory to conventional treatment, showed an improvement in their disability with immunomodulatory agents(IA). Methotrexate had the lowest SE; cyclosporine was associated with severe side effects(SE) and often led to drug discontinuation.







